TABLE 2.
Drug | Target gene | Probe namea | Sequenceb | Temp (°C) | % GC |
---|---|---|---|---|---|
Rifampin | rpoB | RMP-W511L | 5′-T15-CAGCCAGCTGAGCCAATTCA-3′ | 54 | 67 |
RMP-M511P | 5′-T15-AGCCAGCCGAGCCAA-3′ | 47 | 55 | ||
RMP-W513Q | 5′-T15-CTGAGCCAATTCATG-3′ | 39 | 47 | ||
RMP-M513L | 5′T15-CTGAGCCTATTCATGG-3′ | 43 | 50 | ||
RMP-W516D | 5′-T15-TTCATGGACCAGAACA-3′ | 41 | 44 | ||
RMP-M516V | 5′-T15-TTCATGGTCCAGAACA-3′ | 41 | 44 | ||
RMP-M516Y | 5′-T15-ATTCATGTACCAGAACA-3′ | 40 | 35 | ||
RMP-W522S | 5′-T15-CTGTCGGGGTTGAC-3′ | 43 | 64 | ||
RMP-M522L | 5′-T15-CTGTTGGGGTTGAC-3′ | 40 | 57 | ||
RMP-W526H | 5′-T15-GTTGACCCACAAGCGCCGA-3′ | 55 | 63 | ||
RMP-M526Y | 5′-T15-GGTTGACCTACAAGCGC-3′ | 49 | 59 | ||
RMP-M526D | 5′-T15-GGTTGACCGACAAGCGC-3′ | 52 | 65 | ||
RMP-M526R | 5′-T15-TTGACCCGCAAGCGC-3′ | 47 | 67 | ||
RMP-M526L | 5′-T15-TTGACCCTCAAGCGC-3′ | 45 | 60 | ||
RMP-M526P | 5′-T15-TTGACCCCCAAGCGC-3′ | 47 | 67 | ||
RMP-W531S | 5′-T15-CGACTGTCGGCGCTG-3′ | 50 | 73 | ||
RMP-M531L | 5′-T15-CGACTGTTGGCGCTG-3′ | 47 | 67 | ||
RMP-M531W | 5′-T15-CCGACTGTGAGCGCT-3′ | 47 | 67 | ||
RMP-W533L | 5′-T15-GGCGCTGGGGCCCGGC-3′ | 61 | 94 | ||
RMP-M533P | 5′-T15-GTCGGCGCCGGGGCCCG-3′ | 64 | 94 | ||
Isoniazid | katG | INH-W315S | 5′-T15-ATCACCAGCGGCATC-3′ | 45 | 60 |
INH-M315T | 5′-T15-ATCACCACCGGCATC-3′ | 45 | 60 | ||
INH-M315N | 5′-T15-ATCACCAACGGCATC-3′ | 42 | 53 | ||
inhA | inhA-W | 5′-T15-GGCGAGACGATAGGT-3′ | 57 | 60 | |
inhA-M | 5′-T15-GGCGAGATGATAGGT-3′ | 56 | 52 |
W, wild type; M, mutant. Numbers and letters following W or M refer to amino acid types encoded by the codon at the mutation region.
In each sequence, the underlined letter is the position of the potential mismatch.